XNPT : Raghuram, an analyst at the Center to prepare for reduced Hapoalim Securities Company XenoPort (Nasdaq: XNPT) from “buy” to “sell”. XNPT target price is set to $ 10.
According to Hapoalim Securities and Food and Drug Administration rejected XNPT, Glaxo Smith Kline, Inc. (NYSE: GSK) prodrug gabapentin, Horizant, pointing out that the presence of tumors in the pancreatic acinar mice given doses of gabapentin to make safety risks are too large for consideration in the approval the Horizant at this time. “In our view, while this seems arbitrary decision and be expected given the long history of use and safety of gabapentin in human patients for a wide range of disorders, it is still a very big setback, and materials necessary for XenoPort”, says the analyst.
“We believe that unless a path to the approval of Horizant is to clarify, XenoPort shares are likely to face considerable pressure, and adds the analyst.
No comments:
Post a Comment